RA Capital Management 13F holdings, Q4 2017
Holdings as of December 31, 2017 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 27 US equity positions worth $1.2bn in its Q4 2017 13F filing. The largest position was WVE at 22.1% of the reported book, followed by ASND and AVEXIS INC. Against the Q3 2017 filing, it opened 8 new positions, added to 4 and reduced 6 among the top 27 holdings.
What did RA Capital Management own in Q4 2017? Top 27 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2017 |
|---|---|---|---|---|---|---|---|
| 1 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 22.1% | $263.7m | 7,512,049 | 6% | added |
| 2 | ASND ASCENDIS PHARMA A S | Healthcare | 18.7% | $223.6m | 5,580,690 | 0% | held |
| 3 | AVEXIS INC | 10.8% | $129.6m | 1,171,278 | -5% | reduced | |
| 4 | SG7 SAGE THERAPEUTICS INC | 6.3% | $75.0m | 455,173 | – | new | |
| 5 | INFLARX NV | 5.0% | $60.3m | 2,876,080 | – | new | |
| 6 | BIOHAVEN PHARMACTL HLDG CO LTD | 4.5% | $53.9m | 1,997,278 | 0% | held | |
| 7 | ZOGENIX INC | 3.8% | $45.9m | 1,145,268 | 15% | added | |
| 8 | DICERNA PHARMACEUTICALS INC | 3.8% | $44.8m | 4,965,513 | 104% | added | |
| 9 | KALA PHARMACEUTICALS INC | 3.3% | $39.1m | 2,113,236 | 0% | held | |
| 10 | MYOVANT SCIENCES LTD | 3.0% | $35.8m | 2,830,455 | 0% | held | |
| 11 | SCPHARMACEUTICALS INC | 2.9% | $34.5m | 2,857,143 | – | new | |
| 12 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 2.9% | $34.3m | 6,984,692 | 0% | held |
| 13 | KDMN KADMON HLDGS INC | 1.9% | $22.7m | 6,269,342 | -6% | reduced | |
| 14 | APELLIS PHARMACEUTICALS INC | 1.6% | $19.5m | 900,000 | – | new | |
| 15 | SPRO SPERO THERAPEUTICS INC | Healthcare | 1.2% | $14.4m | 1,225,647 | – | new |
| 16 | ENDOCYTE INC | 1.2% | $14.4m | 3,364,648 | – | new | |
| 17 | AVEO PHARMACEUTICALS INC | 1.2% | $14.1m | 5,062,759 | -55% | reduced | |
| 18 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.2% | $14.1m | 1,441,070 | 144% | added | |
| 19 | RA PHARMACEUTICALS INC | 1.0% | $11.5m | 1,351,808 | 0% | held | |
| 20 | SUNESIS PHARMACEUTICALS INC | 1.0% | $11.4m | 3,096,840 | – | new | |
| 21 | CLEMENTIA PHARMACEUTICALS INC COM NPV | 0.9% | $11.1m | 585,403 | 0% | held | |
| 22 | KRYS KRYSTAL BIOTECH INC | Healthcare | 0.6% | $7.4m | 700,000 | 0% | held |
| 23 | ARGX ARGENX SE | Healthcare | 0.4% | $4.8m | 75,816 | – | new |
| 24 | G1 THERAPEUTICS INC | 0.3% | $3.2m | 159,780 | -94% | reduced | |
| 25 | PROTEON THERAPEUTICS INC | 0.2% | $2.5m | 1,337,462 | 0% | held | |
| 26 | CHIASMA INC | 0.2% | $2.0m | 1,176,806 | -16% | reduced | |
| 27 | ACHILLION PHARMACEUTICALS INC | 0.1% | $1.7m | 585,890 | -96% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.